This has reference to our letter dated April 26, 2025, The Board of Directors of the Company at their meeting held on May 07, 2025 have resolved as follows: Pursuant to Regulation 33 ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 3.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transgene Biotek reported its audited results for FY25, posting a net loss of Rs 67.61 lakhs (slightly wider than Rs 65.55 lakhs loss in FY24), with revenue from operations at just Rs 26.07 lakhs (up modestly from Rs 23.49 lakhs). Total income jumped to Rs 104.42 lakhs (vs Rs 41.76 lakhs) largely due to a sharp rise in other income. Standalone equity remains deeply negative at Rs -756.75 lakhs, indicating accumulated losses exceed share capital. The statutory auditor (M/s Vasavi & Co) issued an unmodified (clean) opinion on the results. Management flagged a major overhang: the Enforcement Directorate has imposed a Rs 203.02 crore penalty related to an old GDR issue, which the company is contesting at the Appellate Tribunal. The management said it raised secured debt to clear dues to BIRAC and noted that oral insulin clinical trials are progressing without side effects.
The Rs 203 crore ED penalty is many times larger than the company's standalone asset base (~Rs 34 crore), making it a critical risk overhang for shareholders despite the clean audit opinion. Persisting losses and negative standalone net worth keep the stock speculative and risky in the near term.